Camp4 Therapeutics Corp
No SEC Form 4 filings for $CAMP in the last 30 days.
Campus Activewear shares rose about 6.7% to Rs 251.85 after the company reported strong Q4 FY26 results. Profit after tax increased 25.8% YoY to Rs 44.1 crore; revenue from operations grew 12.3% to Rs 455.6 crore and EBITDA rose 15.4% to Rs 88.5 crore. For FY26, revenue from operations grew 11.4% to Rs 1,774.1 crore.
CAMP4 Therapeutics announced a non-qualified stock option grant for 5,000 shares to a new employee as an inducement, in accordance with Nasdaq Listing Rule 5635(c)(4). The grant, with an exercise price of $4.31, vests over four years, aligning with the company's biopharmaceutical focus on developing regulatory RNA-targeting therapeutics.
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) experienced a 14.2% decrease in short interest during March, settling at 414,235 shares, representing about 1.2% of its outstanding shares. Despite this, the company reported disappointing quarterly earnings, missing analyst consensus with an EPS of ($0.87) against an expected ($0.31). Analysts maintain a "Moderate Buy" rating with an average target price of $8.60, even as the company faces significant profitability challenges.
